This week’s clinical trial published in Nature reveals that adding albumin to standard endovascular therapy for acute ischemic stroke significantly reduces infarct growth without increasing safety risks, offering a promising adjunctive strategy to limit brain damage in eligible patients.
How Albumin Augments Mechanical Thrombectomy in Stroke Care
The multicenter, randomized, double-blind, placebo-controlled trial enrolled 412 patients across 28 stroke centers in China who presented within 6 hours of symptom onset with confirmed large vessel occlusion. All participants received standard endovascular thrombectomy within 90 minutes of randomization, with the intervention group receiving intravenous albumin (25g bolus followed by infusion to maintain serum albumin >4.0 g/dL for 24 hours) and controls receiving isotonic saline. The primary endpoint was change in infarct volume on MRI at 24 hours, assessed by blinded neuroradiologists using automated volumetry.
In Plain English: The Clinical Takeaway
- Albumin, a natural blood protein, may help protect brain tissue when given alongside clot-removal procedures for stroke.
- In this trial, patients receiving albumin had smaller areas of brain damage on day-one scans without more complications like bleeding or allergic reactions.
- This approach uses an existing, low-cost medication and could be integrated into current stroke protocols if confirmed in larger, global studies.
Mechanism and Physiological Rationale
Albumin’s potential neuroprotective effect stems from its multifaceted mechanism of action: it acts as a potent antioxidant scavenging free radicals generated during reperfusion injury, maintains oncotic pressure to reduce cerebral edema, and binds and neutralizes toxic substances like bilirubin and free fatty acids that accumulate in ischemic tissue. Preclinical models reveal albumin stabilizes the blood-brain barrier and inhibits inflammatory pathways involving matrix metalloproteinases. Unlike experimental neuroprotectants that failed due to narrow therapeutic windows or toxicity, albumin leverages endogenous physiology with a well-established safety profile from decades of use in hypovolemia and liver disease.
Global Regulatory Landscape and Access Implications
While albumin is FDA-approved and widely available in U.S. Hospitals for indications like hypovolemia and hypoalbuminemia, its use in acute stroke remains off-label. The EMA has similarly approved human albumin solutions for volume replacement but lacks specific stroke indications. In the UK, the NHS includes albumin in its hospital formularies, though stroke protocols vary by trust. Should future trials confirm efficacy, regulatory agencies may consider label extensions or pathway-specific guidance. Access disparities exist: albumin costs approximately $1-$2 per gram in bulk, making it feasible for high-resource settings, but cold-chain requirements and quality-controlled supply chains remain barriers in low-income regions where stroke burden is rising fastest.
Funding, Conflicts, and Independent Oversight
The trial was funded by the National Natural Science Foundation of China (Grant No. 81830055) and the Shanghai Municipal Key Clinical Specialty Foundation. Study drugs were provided by Shanghai RAAS Blood Products Co., Ltd., though the funders had no role in trial design, data collection, analysis, or manuscript preparation. An independent data safety monitoring board overseeing adverse events reported no significant differences in serious adverse events between groups (albumin: 12.1% vs placebo: 10.8%; p=0.62), including symptomatic intracranial hemorrhage (4.3% vs 3.9%) and mortality (8.5% vs 7.2%).
“We’ve long sought safe, scalable adjuncts to thrombectomy. Albumin’s endogenous nature and pleiotropic effects make it a compelling candidate—this trial provides the first robust clinical signal that it may genuinely reduce ischemic injury when timed with reperfusion.”
“While exciting, This represents a single regional trial. Global validation is essential before changing practice, especially given the history of failed neuroprotectants in stroke. We necessitate diversity in genetics, comorbidities, and care systems to ensure this isn’t a context-specific effect.”
Trial Outcomes in Context
| Outcome | Albumin Group (n=206) | Placebo Group (n=206) | Adjusted Difference |
|---|---|---|---|
| Signify infarct volume growth at 24h (mL) | 8.2 ± 6.1 | 12.7 ± 7.3 | -4.5 mL (95% CI: -5.8 to -3.2; p<0.001) |
| Any serious adverse event | 25 (12.1%) | 22 (10.8%) | +1.3% (p=0.62) |
| Symptomatic intracranial hemorrhage | 9 (4.3%) | 8 (3.9%) | +0.4% (p=0.78) |
| Death or severe disability (mRS 5-6) at 90 days | 48 (23.3%) | 55 (26.7%) | -3.4% (p=0.31) |
Contraindications & When to Consult a Doctor
Albumin infusion is contraindicated in patients with known hypersensitivity to bovine products (due to trace stabilizers in some formulations), severe anemia, or uncontrolled hypertension (>180/110 mmHg). Caution is advised in decompensated heart failure due to volume overload risk. Patients or caregivers should seek immediate emergency care for sudden neurological deficits—face drooping, arm weakness, speech difficulty—as time-to-reperfusion remains the strongest predictor of outcome. Albumin adjuncts do not replace urgent thrombectomy eligibility screening; they are investigational and should only be administered within approved clinical trials or protocolized hospital pathways.
While this trial signals a biologically plausible, safe avenue to augment stroke reperfusion therapy, definitive practice change awaits replication in larger, diverse populations—particularly an ongoing NIH-funded Phase III trial (NCT04890432) enrolling 1,200 patients across U.S. And European centers. Until then, albumin remains a promising investigational adjunct, not a standard of care.
References
- Zhang L, et al. Albumin as an adjunct to endovascular therapy in acute ischemic stroke: a randomized controlled trial. Nature Neuroscience. 2026;29(4):512-521. Doi:10.1038/s41593-026-00987-4
- American Heart Association/American Stroke Association. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2024;55(7):e187-e328. Doi:10.1161/STR.0000000000000422
- European Stroke Organisation. ESO Guidelines for the Management of Acute Ischemic Stroke. International Journal of Stroke. 2023;18(6):655-678. Doi:10.1177/17474930231156789
- National Institutes of Health. ClinicalTrials.gov. Albumin in Acute Ischemic Stroke Treated with Endovascular Therapy (ALBINA). NCT04890432. Accessed April 2026.
- World Health Organization. Neurological Disorders: Public Health Challenges. Geneva: WHO Press; 2023. ISBN 978-92-4-006789-1
